SNSarah Nikiforow

Sarah Nikiforow

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah Nikiforow has a total of 136 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real‐world experience

    by Sara Close, Jun Liu, Lara Abousamra, Ekaterina Konshina, Claire Shao, Eileen Green, Suhayla Sarhan, Kristine Geary, Sanjana Shah, John Manis, et al.

    Background: Stem cell collection for autologous stem cell transplant after induction therapy remains standard for multiple myeloma (MM). Motixafortide, a novel C‐X‐C motif chemokine receptor 4 (CXCR4) antagonist with prolonged receptor occupancy compared to plerixafor, potentially enhances stem cell mobilization. Direct comparison with plerixafor in MM has not been reported. This quality initiative compares motixafortide + granulocyte colony‐stimulating factor (G‐CSF) versus plerixafor + G‐CSF for stem cell mobilization in MM patients at a single center, assessing feasibility, collection/mobilization outcomes, and safety. Study Design and Methods: A prospective cohort of 30 MM patients receiving motixafortide + G‐CSF was compared to a contemporary, retrospective cohort of covariate‐matched 30 patients receiving plerixafor + G‐CSF. Institutional apheresis procedure practices were followed. Primary outcomes included number of collection days, apheresis procedure duration, and adverse events requiring intervention. Results: Twenty‐nine of 30 motixafortide patients completed mobilization. CD34+ stem cell yields and apheresis procedure times were similar between groups; 27 patients per group reached collection targets in 1 day. Motixafortide recipients experienced more frequent adverse reactions (ARs) than plerixafor recipients. Conclusions: In this first real‐world comparison, use of motixafortide was feasible but not superior to plerixafor for MM mobilization. Motixafortide was associated with substantially higher rates of injection‐site and systemic ARs requiring intervention and imposed additional workflow demands for premedication and post‐injection monitoring. Due to the non‐superiority of motixafortide, decreasing acquisition costs for plerixafor and motixafortide's higher resource utilization, our institution favors continuing plerixafor as the default for MM mobilization. We reserve motixafortide for select patients, with ongoing evaluation of poor mobilizers to clarify its role in collection and post‐transplant outcomes.

  • Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease

    by Corey Cutler, Haesook T. Kim, Hassan El Banna, Elizabeth Halloran, Emily Matozel, Vincent T. Ho, John Koreth, Mahasweta Gooptu, Roman Shapiro, Amar Kelkar, et al.

    PURPOSE: Chronic graft-versus-host disease (cGVHD) is a multisystem alloimmune disorder associated with abnormal B-cell biology and aberrant antibody responses. As B-cell–directed therapy can effectively treat established cGVHD, we tested whether prophylactic B-cell depletion could prevent the development of corticosteroid-requiring cGVHD following allogeneic transplantation. METHODS: We performed a randomized, placebo-controlled, and blinded trial comparing four doses of the B-cell–depleting antibody obinutuzumab (1,000 mg once on days 90, 180, 270, and 365 after transplantation) with placebo in transplant recipients receiving tacrolimus-based GVHD prevention at higher risk of cGVHD. The primary end point was the 1-year incidence of corticosteroid-requiring cGVHD. We measured antibody responses against Y chromosome–encoded minor histocompatibility (H-Y) antigens and correlated their occurrence with corticosteroid-requiring cGVHD incidence. RESULTS: One hundred seventy-eight participants were analyzed. The prophylactic administration of obinutuzumab resulted in profound B-cell depletion, a significant reduction in the incidence of steroid-requiring cGVHD at 1 year (13.3% v 35.2%; P = .0005), and an improvement in immunosuppression-free, relapse-free survival (48% v 34% at 2 years; P = .02). Neutropenia was more common in the obinutuzumab arm, but nonrelapse mortality was not different. In participants without preformed H-Y antibodies at the time of study intervention, obinutuzumab resulted in the most significant reduction in steroid-requiring cGVHD at 12 months (8.6%) compared with obinutuzumab participants with H-Y antibodies (40%) or placebo participants regardless of antibody status (41% with antibodies, 57% without antibodies). CONCLUSION: In allogeneic transplant recipients at higher risk of cGVHD, early B-cell depletion results in a significant reduction in the incidence of corticosteroid-requiring cGVHD.


  • Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma

    by Adam S. Sperling, Benjamin A. Derman, Sarah Nikiforow, Alejandro Alonso, Shuntaro Ikegawa, Nina Orwitz, David S. Quinn, David Pearson, Dexiu Bu, Pedro Milanez-Almeida, et al.

    Traditional manufacturing of B cell maturation antigen (BCMA)–targeted chimeric antigen receptor (CAR) T cell therapies is prolonged, leading to reduced patient access, T cell exhaustion, and consequently limiting therapeutic efficacy. To address this issue, we developed durcabtagene autoleucel, a BCMA-directed CAR T cell therapy manufactured using a rapid platform aimed at preserving T cell stemness. Here, we present the primary findings of part A of a phase 1 study (NCT04318327) of durcabtagene autoleucel in patients with relapsed/refractory multiple myeloma (r/r MM). The primary objective was safety; secondary objectives included response rates, cellular kinetics, immunogenicity, and manufacturing feasibility. Durcabtagene autoleucel was successfully manufactured for all 55 patients (median vein-to-vein time, 24 days) and given as a single infusion at one of four flat target doses (2.5 × 10 6 to 20 × 10 6 CAR T cells). Among all patients, the overall response rate was 98%, and the stringent complete response rate was 55%. Eighty percent of evaluable patients (35 of 44) achieved minimal residual disease negativity. There were no unexpected safety findings and no reports of delayed neurotoxicity. Immunophenotyping and transcriptomic analyses confirmed preservation of a stem-like phenotype in the manufactured final product. On the basis of the safety, efficacy, and cellular expansion results from the phase 1 trial, a phase 2 trial (NCT05172596) was initiated to further explore the efficacy and safety of durcabtagene autoleucel in heavily pretreated patients with aggressive r/r MM.


  • Top Cited Papers

    Hemophagocytic lymphohistiocytosis in adults

    by Joanne I. Hsu, Sarah Nikiforow, Nancy Berliner

    Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hematologic disorder characterized by unchecked immune activation and hyperinflammation, resulting in end-organ tissue damage and high mortality rates in untreated patients. Since the first description of this condition in 1939, our understanding of HLH has continued to deepen, with increasing appreciation of the differences and similarities between primary (familial) HLH and secondary (acquired) HLH. Primary HLH typically presents in the early years of life on the backdrop of inherited genetic mutations affecting cytotoxic immune cell function, whereas secondary HLH more commonly presents in adults and is a heterogeneous disorder with various potential triggers ranging from infections to malignancy, autoimmune disease, immunodeficiency, and medications. However, they converge in a common pathway of widespread systemic inflammation, which clinically manifests with fevers, organomegaly, cytopenias, laboratory derangements, and rapid development of multiorgan failure. As such, early recognition and intervention is critical to prevent irreversible organ damage and death in both primary and secondary HLH. In this review, we focus our attention on adult-onset secondary HLH and explore the latest updates on the pathophysiology, precipitants, clinical presentation, diagnosis, and management of this life-threatening condition. Primary HLH is reviewed separately as a companion article in this review series.


  • Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies

    by Frederick L. Locke, Sarah Nikiforow, Matthew J. Frigault, David G. Maloney, Marco Davila, David B. Miklos, Yi Lin, Judy Vong, Nirav N. Shah, Sattva S. Neelapu, et al.


  • Top Cited Papers
    Open Access

    Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry

    by Samuel John, Kevin J. Curran, Erin M. Hall, Amy K. Keating, Susanne H.C. Baumeister, Sarah Nikiforow, Timothy Driscoll, Amy Moskop, Kevin O. McNerney, Christine L. Phillips, et al.

    Since the first approval of tisagenlecleucel in 2017, pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) may receive this CD19-directed chimeric antigen receptor T-cell therapy. We report real-world data from the Center for International Blood and Marrow Transplant Research (>2.5 years of follow-up). As of 4 May 2022, 768 patients with B-ALL had received tisagenlecleucel. Patients aged ≥18 and <18 years of age (including those <3 years) were treated during first relapse (26.6% and 26.7% [<3 years, 44.8%], respectively) or primary refractory disease (12.4% and 12.1% [<3 years, 15.5%], respectively) with 17.6% and 11.6% (<3 years, 13.8%), respectively, having high disease burden (≥50% bone marrow [BM] blasts) and 20.2% and 20.2% (0 to <5% BM blasts). Among patients with ≥12 months postinfusion follow-up (n = 578; median follow-up, 32.1 months), the best overall response of complete remission/complete remission with incomplete blood count recovery was 86.0%. The 12-month relapse-free survival (RFS) and overall survival (OS) were 61.8% and 79.4%, respectively, whereas the 24-month RFS and OS were 50.3% and 63.8%, respectively. Age (<18 years) and disease burden (<50% BM blasts) were associated with better outcomes. Previous inotuzumab therapy and KMT2A rearrangement were associated with worse outcomes. Older patients (≥18 years) experienced a higher rate of any-grade cytokine release syndrome (CRS) associated with higher disease burden before infusion. Any-grade CRS and neurotoxicity were lower in patients aged <3 years. Extended follow-up continues to demonstrate high rates of RFS and favorable safety in this population.


  • Expression of HLA-B*35 is Associated With an Increased Risk of CMV Viremia and Clinically Significant CMV Infection following PTCy-Based Hematopoietic Cell Transplantation

    by Jessica S. Little, Kyle M. Hebert, Donna S. Neuberg, Sarah Nikiforow, Mahasweta Gooptu, Roman M. Shapiro, John Koreth, Joseph H. Antin, Corey Cutler, Robert J. Soiffer, et al.


  • Open Access

    The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma

    by Adi Zoref-Lorenz, Jun Murakami, Ronit Gurion, Swaminathan P. Iyer, Uri Abadi, Inbar Cohen, Gaurav Goyal, Shehab Mohamed, Sarah Nikiforow, Abd El Haleem Natour, et al.

    Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome that complicates hematologic malignancies. The Optimized HLH Inflammatory (OHI) index, based solely on the combined elevation of soluble CD25 (sCD25; >3900 U/mL) and ferritin (1000 ng/mL) levels, predicts mortality more effectively than the conventional HLH criteria. This study aimed to determine whether mortality in OHI-positive (OHI+) patients is primarily caused by lymphoma or inflammation-related causes. In a multicenter, retrospective study of patients with newly diagnosed lymphoma with sCD25 and ferritin measurements available, patients were classified as OHI+ or OHI negative (OHI−). The 1-year and 3-year overall survival (OS), event-free survival, and causes of death were analyzed, along with predicted vs observed mortality based on other lymphoma-relevant prognostic indexes. Among 135 patients with lymphoma (70 OHI− and 65 OHI+), OHI+ patients had significantly lower OS at 1 year (33% vs 81%; P < .0001) with a median survival of 190 days. OHI+ patients had a 13-fold increased mortality risk (odds ratio, 13.3; 95% confidence interval, 6.0-28.5) despite similar predicted OS based on conventional indexes (72% vs 65%; P = .46). Mortality causes differed significantly. A total of 58% of OHI+ patients died from multiorgan failure, whereas only 6% died from progressive lymphoma. In contrast, 43% of the OHI− patients died from lymphoma progression. The incorporation of etoposide into lymphoma-directed treatment was associated with improved OS in OHI+ T–cell lymphomas (P = .007). These findings underscore the clinical significance of the OHI index as a prognostic tool in lymphoma, to elucidate the mechanisms of mortality, and to identify a high-risk subgroup for which tailored treatments may lead to improved outcomes.


  • Open Access

    Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells

    by Frederick L. Locke, Zahra Mahmoudjafari, Partow Kebriaei, Rebecca A. Gardner, Matthew J. Frigault, Noelle V. Frey, Krishna V. Komanduri, Miguel-Angel Perales, Sarah Nikiforow